Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display & Cocktail

11P - Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study


02 Mar 2020


Poster Display & Cocktail


Eric Angevin


Annals of Oncology (2020) 31 (suppl_1): S1-S7. 10.1016/annonc/annonc86


E. Angevin1, S. Groenland2, T. Bauer3, D. Rischin4, I. Gardeazabal5, V. Moreno6, J.M. Trigo7, M. Chisamore8, J. Shaik9, F. Rigat10, C. Ellis9, H. Chen9, R. Gagnon9, S.J. Scherer9, D. Turner9, S. Yadavilli9, M. Ballas9, A. Hoos9, M. Maio11

Author affiliations

  • 1 Gustave Roussy Institut de Cancérologie, 94805 - Villejuif/FR
  • 2 Antoni van Leeuwenhoek, Netherlands Cancer Institute, Amsterdam/NL
  • 3 Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville/US
  • 4 Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne/AU
  • 5 Hospital Universitario "Marqués de Valdecilla", Santander/ES
  • 6 START Madrid-FJD, University Hospital "Fundacion Jimenez Diaz", Madrid/ES
  • 7 Hospital Universitario Virgen de la Victoria, Málaga/ES
  • 8 Merck & Co., Inc, North Wales/US
  • 9 GSK, Collegeville/US
  • 10 GSK, Stevenage/GB
  • 11 University Hospital of Siena, Siena/IT


Abstract 11P

GSK609 an agonist IgG4 monoclonal antibody (mAb) against inducible co-stimulatory receptor (ICOS) exhibits T cell mediated immune stimulating and anti-tumor activity. INDUCE-1 is the first in human study investigating GSK609 alone and in combinations which include pembrolizumab in select tumor types including recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.